Yeztugo Lenacapavir Is Now the First and Only FDA Approved HIV . . . FOSTER CITY, Calif --(BUSINESS WIRE)-- Gilead Sciences, Inc (Nasdaq: GILD) today announced that the U S Food and Drug Administration (FDA) has approved Yeztugo ® (lenacapavir)—the company’s injectable HIV-1 capsid inhibitor—as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg, making it the first and only twice
FDA approval of injectable lenacapavir marks progress for HIV prevention The World Health Organization (WHO) welcomes the approval by the United States Food and Drug Administration (FDA) of injectable lenacapavir for HIV prevention This milestone follows promising 2024 results from the PURPOSE 1 and PURPOSE 2 trials, which demonstrated the safety and efficacy of lenacapavir across diverse populations and settings
HIV prevention drug hailed as a breakthrough gets FDA approval A drug with the potential to drastically curb the HIV epidemic just cleared its first regulatory hurdle On Wednesday, the Food and Drug Administration approved lenacapavir for the prevention of HIV
FDA approves lenacapavir as a twice-a-year shot to prevent HIV | AP News The Food and Drug Administration has approved the world’s only twice-a-year shot to prevent HIV In two groundbreaking studies, Gilead Sciences’ shot nearly eliminated new infections in people at high risk of HIV A pharmacist holds a vial of lenacapavir, an injectable HIV prevention drug, at the Desmond Tutu Health Foundation’s